Baseline cohort characteristics among older adults with AML enrolled in a randomized PA intervention study
| Characteristics . | Total N = 70 . | PA n = 35 . | Control n = 35 . | P value . |
|---|---|---|---|---|
| % or mean (SD) . | % or mean (SD) . | % or mean (SD) . | ||
| Demographics | ||||
| Age, mean, y | 72.1 (6.3) | 71.8 (6.4) | 72.3 (6.2) | .72 |
| 60-69 | 34.3 | 28.6 | 40.0 | |
| 70-79 | 54.3 | 60.0 | 48.6 | |
| ≥80 | 11.4 | 11.4 | 11.4 | |
| Sex (male) | 70 | 74.3 | 65.7 | .43 |
| Race (White) | 88.6 | 82.9 | 94.3 | .26 |
| Married | 65.7 | 68.6 | 62.9 | .61 |
| Education level (n = 68) | ||||
| Below high school | 12.9 | 17.1 | 8.6 | .50 |
| High school | 30.0 | 31.4 | 28.6 | |
| College/above | 57.1 | 51.4 | 62.9 | |
| Behaviors | ||||
| Self-reported PA (≥3 d/wk) | ||||
| Mild | 38.2 | 37.1 | 39.4 | .85 |
| Moderate | 31.9 | 28.6 | 35.3 | .55 |
| Strenuous | 5.8 | 8.6 | 2.9 | .61 |
| Tobacco | .31 | |||
| Current | 10.0 | 7.1 | 5.7 | |
| Former | 57.1 | 60.0 | 54.3 | |
| Never | 32.9 | 25.7 | 40.0 | |
| Clinical | ||||
| Hemoglobin (n = 68), g/dL | 9.3 (1.6) | 9.2 (1.7) | 9.4 (1.5) | .60 |
| Lactate dehydrogenase, U/L | 522.3 (943.6) | 555.8 (686.6) | 488.7 (1154.7) | .77 |
| White cell count, ×103/μL | 17.7 (36.2) | 22.3 (46.2) | 13.1 (21.9) | .29 |
| Creatinine, mg/dL | 1.1 (0.5) | 1.1 (0.5) | 1.2 (0.5) | .81 |
| Body mass index, kg/m2 | 29.2 (6.1) | 29.6 (7.4) | 28.6 (4.4) | .47 |
| ECOG score (≤1) | 57.1 | 54.3 | 60 | .63 |
| Previous myelodysplastic syndrome | 25.7 | 20.0 | 31.4 | .27 |
| Cytogenetic risk group (n = 69) | ||||
| Favorable | 4.4 | 8.6 | 0 | .31 |
| Intermediate | 62.3 | 57.1 | 67.7 | |
| Poor | 33.3 | 34.3 | 32.3 | |
| Coronary artery disease | 24.3 | 28.6 | 20.0 | .40 |
| Chronic obstructive pulmonary disease | 10.0 | 14.3 | 5.7 | .43 |
| Diabetes mellitus | 34.3 | 22.9 | 45.7 | .04 |
| Congestive heart failure | 4.3 | 5.7 | 2.9 | 1.0 |
| Prior cancer | 34.3 | 34.3 | 34.3 | 1.0 |
| Renal dysfunction | 10.0 | 8.6 | 11.4 | 1.0 |
| HCT-CI | 2.0 (1.8) | 2.1 (2.0) | 2.0 (1.8) | .90 |
| Induction treatment, anthracycline + cytarabine | 77.1 | 82.9 | 71.4 | .25 |
| Geriatric assessment measures | ||||
| PAT-D (n = 62) (range, 1-5; impairment >1) at the time of treatment | 1.8 (0.7) | 1.9 (0.7) | 1.7 (0.6) | .37 |
| Activities of Daily Living subscale (n = 67) | 1.4 (0.5) | 1.4 (0.4) | 1.4 (0.5) | .96 |
| Instrumental Activities of Daily Living subscale (n = 63) | 1.6 (0.7) | 1.6 (0.8) | 1.5 (0.6) | .68 |
| Mobility subscale (n = 66) | 2.5 (1.2) | 2.7 (1.3) | 2.3 (1.2) | .13 |
| SPPB (range, 0-9; impairment <9; n = 68) | 7.0 (3.8) | 7.1 (3.7) | 6.8 (4.1) | .73 |
| SPPB score of <9 (n = 68), % | 52.9 | 54.3 | 51.5 | .82 |
| SPPB walk score (range, 0-4) | 2.5 (1.5) | 2.7 (1.5) | 2.4 (1.5) | .44 |
| SPPB balance score (range, 0-4) | 2.8 (1.5) | 2.9 (1.5) | 2.7 (1.6) | .67 |
| SPPB chair stand score (range, 0-4) | 1.7 (1.4) | 1.6 (1.3) | 1.8 (1.4) | .57 |
| MAT-SF (n = 66) | 53.1 (11.3) | 51.7 (11.1) | 54.8 (11.3) | .26 |
| Grip strength (kg) | ||||
| Male (n = 47) | 34.9 (9.5) | 33.9 (8.6) | 36.0 (10.6) | .46 |
| Female (n = 20) | 21.2 (5.4) | 23.1 (4.3) | 19.5 (5.9) | .15 |
| Distress thermometer (n = 69) | 4.6 (3.1) | 4.9 (3.1) | 4.4 (3.1) | .55 |
| CES-D (n = 69) | 12.0 (7.7) | 13.4 (8.2) | 10.5 (8.9) | .15 |
| FACT-Leu (n = 68) | 127.4 (19) | 127.5 (18.7) | 127.2 (19.7) | .95 |
| FACT-Emotional (n = 68) | 18.9 (3.5) | 18.6 (3.7) | 19.2 (3.3) | .50 |
| FACT-Functional (n = 68) | 16.6 (6.3) | 16.9 (5.9) | 16.4 (6.7) | .72 |
| FACT-G (n = 68) | 80.8 (13.0) | 80.9 (13.2) | 80.7 (12.9) | .95 |
| FACT-Physical (n = 69) | 21.6 (5.0) | 21.3 (5.1) | 21.9 (5.0) | .62 |
| FACT-Social (n = 69) | 23.7 (3.9) | 24.1 (4.2) | 23.3 (3.5) | .37 |
| FACT-Fatigue (n = 69) | 31.9 (11.4) | 31.9 (9.9) | 32.0 (12.9) | .97 |
| Digit symbol substitution test (n = 64) | 36.1 (13.0) | 34.4 (13.7) | 38.0 (12.2) | .27 |
| Characteristics . | Total N = 70 . | PA n = 35 . | Control n = 35 . | P value . |
|---|---|---|---|---|
| % or mean (SD) . | % or mean (SD) . | % or mean (SD) . | ||
| Demographics | ||||
| Age, mean, y | 72.1 (6.3) | 71.8 (6.4) | 72.3 (6.2) | .72 |
| 60-69 | 34.3 | 28.6 | 40.0 | |
| 70-79 | 54.3 | 60.0 | 48.6 | |
| ≥80 | 11.4 | 11.4 | 11.4 | |
| Sex (male) | 70 | 74.3 | 65.7 | .43 |
| Race (White) | 88.6 | 82.9 | 94.3 | .26 |
| Married | 65.7 | 68.6 | 62.9 | .61 |
| Education level (n = 68) | ||||
| Below high school | 12.9 | 17.1 | 8.6 | .50 |
| High school | 30.0 | 31.4 | 28.6 | |
| College/above | 57.1 | 51.4 | 62.9 | |
| Behaviors | ||||
| Self-reported PA (≥3 d/wk) | ||||
| Mild | 38.2 | 37.1 | 39.4 | .85 |
| Moderate | 31.9 | 28.6 | 35.3 | .55 |
| Strenuous | 5.8 | 8.6 | 2.9 | .61 |
| Tobacco | .31 | |||
| Current | 10.0 | 7.1 | 5.7 | |
| Former | 57.1 | 60.0 | 54.3 | |
| Never | 32.9 | 25.7 | 40.0 | |
| Clinical | ||||
| Hemoglobin (n = 68), g/dL | 9.3 (1.6) | 9.2 (1.7) | 9.4 (1.5) | .60 |
| Lactate dehydrogenase, U/L | 522.3 (943.6) | 555.8 (686.6) | 488.7 (1154.7) | .77 |
| White cell count, ×103/μL | 17.7 (36.2) | 22.3 (46.2) | 13.1 (21.9) | .29 |
| Creatinine, mg/dL | 1.1 (0.5) | 1.1 (0.5) | 1.2 (0.5) | .81 |
| Body mass index, kg/m2 | 29.2 (6.1) | 29.6 (7.4) | 28.6 (4.4) | .47 |
| ECOG score (≤1) | 57.1 | 54.3 | 60 | .63 |
| Previous myelodysplastic syndrome | 25.7 | 20.0 | 31.4 | .27 |
| Cytogenetic risk group (n = 69) | ||||
| Favorable | 4.4 | 8.6 | 0 | .31 |
| Intermediate | 62.3 | 57.1 | 67.7 | |
| Poor | 33.3 | 34.3 | 32.3 | |
| Coronary artery disease | 24.3 | 28.6 | 20.0 | .40 |
| Chronic obstructive pulmonary disease | 10.0 | 14.3 | 5.7 | .43 |
| Diabetes mellitus | 34.3 | 22.9 | 45.7 | .04 |
| Congestive heart failure | 4.3 | 5.7 | 2.9 | 1.0 |
| Prior cancer | 34.3 | 34.3 | 34.3 | 1.0 |
| Renal dysfunction | 10.0 | 8.6 | 11.4 | 1.0 |
| HCT-CI | 2.0 (1.8) | 2.1 (2.0) | 2.0 (1.8) | .90 |
| Induction treatment, anthracycline + cytarabine | 77.1 | 82.9 | 71.4 | .25 |
| Geriatric assessment measures | ||||
| PAT-D (n = 62) (range, 1-5; impairment >1) at the time of treatment | 1.8 (0.7) | 1.9 (0.7) | 1.7 (0.6) | .37 |
| Activities of Daily Living subscale (n = 67) | 1.4 (0.5) | 1.4 (0.4) | 1.4 (0.5) | .96 |
| Instrumental Activities of Daily Living subscale (n = 63) | 1.6 (0.7) | 1.6 (0.8) | 1.5 (0.6) | .68 |
| Mobility subscale (n = 66) | 2.5 (1.2) | 2.7 (1.3) | 2.3 (1.2) | .13 |
| SPPB (range, 0-9; impairment <9; n = 68) | 7.0 (3.8) | 7.1 (3.7) | 6.8 (4.1) | .73 |
| SPPB score of <9 (n = 68), % | 52.9 | 54.3 | 51.5 | .82 |
| SPPB walk score (range, 0-4) | 2.5 (1.5) | 2.7 (1.5) | 2.4 (1.5) | .44 |
| SPPB balance score (range, 0-4) | 2.8 (1.5) | 2.9 (1.5) | 2.7 (1.6) | .67 |
| SPPB chair stand score (range, 0-4) | 1.7 (1.4) | 1.6 (1.3) | 1.8 (1.4) | .57 |
| MAT-SF (n = 66) | 53.1 (11.3) | 51.7 (11.1) | 54.8 (11.3) | .26 |
| Grip strength (kg) | ||||
| Male (n = 47) | 34.9 (9.5) | 33.9 (8.6) | 36.0 (10.6) | .46 |
| Female (n = 20) | 21.2 (5.4) | 23.1 (4.3) | 19.5 (5.9) | .15 |
| Distress thermometer (n = 69) | 4.6 (3.1) | 4.9 (3.1) | 4.4 (3.1) | .55 |
| CES-D (n = 69) | 12.0 (7.7) | 13.4 (8.2) | 10.5 (8.9) | .15 |
| FACT-Leu (n = 68) | 127.4 (19) | 127.5 (18.7) | 127.2 (19.7) | .95 |
| FACT-Emotional (n = 68) | 18.9 (3.5) | 18.6 (3.7) | 19.2 (3.3) | .50 |
| FACT-Functional (n = 68) | 16.6 (6.3) | 16.9 (5.9) | 16.4 (6.7) | .72 |
| FACT-G (n = 68) | 80.8 (13.0) | 80.9 (13.2) | 80.7 (12.9) | .95 |
| FACT-Physical (n = 69) | 21.6 (5.0) | 21.3 (5.1) | 21.9 (5.0) | .62 |
| FACT-Social (n = 69) | 23.7 (3.9) | 24.1 (4.2) | 23.3 (3.5) | .37 |
| FACT-Fatigue (n = 69) | 31.9 (11.4) | 31.9 (9.9) | 32.0 (12.9) | .97 |
| Digit symbol substitution test (n = 64) | 36.1 (13.0) | 34.4 (13.7) | 38.0 (12.2) | .27 |
CES-D, Center for Epidemiologic Studies Depression scale; FACT-G, Functional Assessment of Cancer Therapy-General; HCT-CI, hematopoietic cell transplantation–specific comorbidity index; MAT-SF, Mobility Assessment Tool–short form; PAT-D, Pepper Assessment Tool for Disability.